| 引用本文: |
刘晓清,谭涵宇,彭俊,秦惠钰,田野,陈梅,吴权龙,彭清华.散血明目片防控增殖性玻璃体视网膜病变的机制研究[J].湖南中医药大学学报,2020,40(7):777-783[点击复制] |
|
| |
|
|
| 本文已被：浏览 1812次 下载 522次 |
| 散血明目片防控增殖性玻璃体视网膜病变的机制研究 |
| 刘晓清,谭涵宇,彭俊,秦惠钰,田野,陈梅,吴权龙,彭清华 |
| (湖南中医药大学, 湖南 长沙 410208;湖南中医药大学第一附属医院, 湖南 长沙 410007;达州市中心医院, 四川 达州 635000) |
| 摘要: |
| 目的 观察散血明目片对兔外伤性增殖性玻璃体视网膜病变（proliferative vitreoretinopathy，PVR）模型中增殖信号通路相关蛋白PI3K、Akt、P38MAPK、MEK表达的影响，探讨散血明目片对兔外伤性PVR的防治作用。方法 实验以42只新西兰大白兔为对象，采用巩膜穿通法联合向玻璃体腔注射富含血小板血浆形成PVR模型，随机分为7组，每组6只，分别为：A组空白组、B组模型组、C组散血明目片组、D组PD98059组、E组LY294002组、F组MK-2206组、G组抑制剂混合组。造模后30 min，D组、E组、F组、G组分别向玻璃体腔注射0.1 mL的PD98059、LY294002、MK-2206及3种混合抑制剂。B、C组则予以玻璃体腔内注射0.1 mL生理盐水。术后第1天C组予以散血明目片10 mg/kg溶液灌胃，除A组外其余组以生理盐水10 mL/kg灌胃，连续灌胃28 d。28 d后采用B超观察术眼玻璃体、眼底情况；取材后采用免疫组化法、RT-qPCR法对送检组织进行相关蛋白表达的测定。结果 B超结果显示散血明目片能抑制兔PVR中视网膜的增殖，维持视网膜正常形态。免疫组化与RT-qPCR检测结果显示，散血明目片能有效降低兔视网膜及增殖膜中PI3K、Akt、MEK、P38MAPK的表达，其中以下调PI3K、Akt、P38MAPK的表达更显著。结论 散血明目片可抑制PVR的发生与发展，降低视网膜及增殖膜中相关增殖蛋白的表达，其防治PVR方面可能与MAPK、PI3K/Akt信号通路有关。 |
| 关键词: 增殖性玻璃体视网膜病变 散血明目片 丝裂原活化蛋白激酶 磷脂酰肌醇3-激酶/蛋白激酶B |
| DOI：10.3969/j.issn.1674-070X.2020.07.001 |
| 投稿时间：2020-04-01 |
| 基金项目:国家自然科学青年基金项目（8180151970）；中医药防治五官科疾病湖南省重点实验室建设项目（2017TP1018）；湖南省中医药防治耳鼻喉疾病与视功能保护工程研究中心开放基金项目（2018YGCO4）；湖南省中药药管理局科研项目（201622）；湖南省研究生科研创新项目（CX2018B499，CX2018B490）；国家中医药管理局中医眼科学重点学科建设项目（国家中医药〔2009〕30号）。 |
|
| Study on Mechanism of Sanxue Mingmu Tablets in Preventing and Controlling Proliferative Vitreoretinopathy |
| LIU Xiaoqing,TAN Hanyu,PENG Jun,QIN Huiyu,TIAN Ye,CHEN Mei,WU Quanlong,PENG Qinghua |
| (Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;Dazhou Central Hospital of Sichuan Province, Dazhou, Sichuan 635000, China) |
| Abstract: |
| Objective To observe the effects of Sanxue Mingmu Tablets on the expression of proliferation signal pathway related proteins PI3K, AKT, P38MAPK and MEK in a traumatic proliferative vitreoretinopathy (PVR) model of rabbits, and to explore the effects of Sanxue Mingmu Tablets in preventing and treating proliferative vitreoretinopathy. Methods For the experiment, 42 New Zealand white rabbits were used as subjects, and the scleral penetration method was combined with the injection of platelet-rich plasma into the vitreous cavity to establish a PVR model. They were randomly divided into 7 groups, with 6 rabbits in each group. They were group A:blank group; group B:model group; group C:Sanxue Mingmu Tablets group; group D:PD98059 group; group E:LY294002 group; group F:MK-2206 group; group G:inhibitor mixed group. In 30 minutes after modeling, 0.1 mL of PD98059, LY294002, MK-2206 and 3 kinds of mixed inhibitors were injected into the vitreous cavity to group D, group E, group F and group G, respectively. In group B and C, 0.1 mL of normal saline was injected into the vitreous cavity. On the first day after operation, the group C was administered with 10 mg/kg solution of Sanxue Mingmu Tablets by gavage. The other groups were intragastrically administered with 10 mL/kg normal saline for 28 days. After 28 days, the vitreous and fundus conditions were observed with B-ultrasound; After the samples were taken, immunohistochemistry and RT-qPCR were used to determine the protein expression of the submitted tissues. Results B-ultrasound showed that Sanxue Mingmu Tablets could inhibit the retina proliferation in rabbit PVR and maintain normal retinal shape. Immunohistochemistry and RT-qPCR showed that Sanxue Mingmu Tablets could effectively reduce the expression of PI3K, AKT, MEK, P38MAPK in the retina and proliferating membrane of rabbits, but the down-regulation of PI3K, Akt, P38MAPK was more significant. Conclusion Sanxue Mingmu Tablets can inhibit the occurrence and development of PVR and reduce the expression of related proliferative proteins in the retina and proliferating membrane. The prevention and treatment of PVR may be related to the MAPK and PI3K/Akt signaling pathways. |
| Key words: proliferative vitreoretinopathy Sanxue Mingmu Tablets MAPK PI3K/Akt |
|
二维码（扫一下试试看！） |
|
|
|
|
